New Release of SureSource Engage (Formerly CentrosHealth) Helps Clinical Trial Sponsors Collaborate More Effectively with Patients Around the World.
PHILADELPHIA, PA & CAMBRIDGE, MA – November, 18 2016 – Clinical Ink, the pioneering provider of eSource and patient engagement technologies for clinical trials, today announced the latest release of SureSource Engage®, enabling clinical trial sponsors and contract research organizations (CROs) to significantly increase patient adherence, retention and data quality by engaging with patients using their mobile devices. The new release of SureSource Engage (formerly CentrosHealth) is part of Clinical Ink’s SureSource platform. The new release now supports a broad array of languages and includes performance and usability enhancements that makes it easier for patients to collaborate and share study data with clinical trial sponsors.
“Innovation in this area helps improve patient retention and adherence instead of the traditional churn and burn approach of simply recruiting more patients,” said Ed Seguine, CEO, Clinical Ink. “SureSource Engage enables researchers to focus on the patients they have, yielding a more coherent way to bring new drugs to market and a more efficient approach to executing clinical trials.”
New SureSource Engage capabilities include:
- Extended support for 39 languages, for broader regional coverage
- Expanded sensor connectivity with Qualcomm Life 2net Mobile Hub to support more trackers, monitors, meters and scales
- Simplified mobile download access from the Apple App Store and Google Play Store
- Increased data access via easy to view dashboards
Joe Alea, Clinical Ink’s CTO, added: “Clinical Ink’s patient engagement and eCOA platform is not only supporting trials around the globe, it’s adding an entirely new dimension to the current trial technology options and fostering stronger partnerships between clinical research sites and patients. It’s a powerful tool for sponsors and their outsourcing partners to address recruitment challenges head on by improving retention and adherence.”
Since its commercial launch in 2012, Clinical Ink has emerged as an innovation leader with its eSource and patient engagement platform. The SureSource platform eliminates the need for separate EDC, eCOA, and ePRO applications while reducing the cost, complexity, and time associated with data management and monitoring activities. SureSource collects documents and data from sites and patients in real time, providing sponsors with timely, data-based insights into protocol execution, data quality, trial surveillance, and GCP compliance that are impossible with legacy EDC/eCOA/ePRO systems and current practices.
About Clinical Ink
Founded in 2007, Clinical Ink® is transforming clinical development with innovative technologies that make clinical research easier for sites, sponsors and patients. Clinical Ink’s SureSource® comprehensive platform directly captures eSource data and documents and improves patient engagement by focusing on the critical moments that matter when executing the protocol. Clinical Ink maintains offices in Cambridge, MA, Winston-Salem, NC, and Philadelphia, PA. Find more at www.clinicalink.com.
Media Contact: Rob Quinn | 336.728.6830 | firstname.lastname@example.org